ABSI | Absci Corporation Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.79 - 5.41
52 Week Range	2.4500 - 6.72
Beta	2.00
Implied Volatility	150.79%
IV Rank	62.16%
Day's Volume	4,899,121
Average Volume	4,976,749
Shares Outstanding	114,856,000
Market Cap	569,685,760
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-07-22

Valuation
Profitability
Growth
Health
P/E Ratio	-5.33
Forward P/E Ratio	N/A
EPS	-0.93
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	155
Country	USA
Website	ABSI

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

ABSI's peers: RXRX, AFMD, SANA, RLAY, EXAI, VECT, ZURA, ELEV, ICVX, AVRO, HEPA, DTIL, CRBU, CFRX, GRPH, DAWN, ABOS, XFOR, INZY, ADVM, CYCCP, XBIT

*Chart delayed

Analyzing fundamentals for ABSI we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see ABSI Fundamentals page.

Watching at ABSI technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on ABSI Technicals page.